anlotinib + etoposide + cisplatin

Anlotinib + etoposide + cisplatin is a combination regimen used primarily as first-line therapy for extensive-stage small cell lung cancer (ES-SCLC). Anlotinib is a multi-targeted tyrosine kinase inhibitor that inhibits vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR), platelet-derived growth factor receptor (PDGFR), and c-Kit, thereby blocking angiogenesis and tumor proliferation. Etoposide is a topoisomerase II inhibitor that induces DNA strand breaks, leading to apoptosis in rapidly dividing cells. Cisplatin is a platinum-based chemotherapeutic agent that forms DNA crosslinks, inhibiting DNA synthesis and function. This combination has demonstrated improved progression-free survival (PFS), overall survival (OS), objective response rate (ORR), and disease control rate (DCR) compared to standard regimens, with manageable safety profiles in clinical studies[1][2][4][5]. The regimen typically involves several cycles of all three drugs followed by maintenance therapy with anlotinib.

Other names

anlotinib plus etoposide and cisplatinanlotinib combined with EP regimen